MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.thromres.2025.109580

Медицинская библиотека · Thrombosis research · 2026

Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric study.

Chovi-Trull Maria, Megías-Vericat Juan Eduardo, Palanques-Pastor Tomás, Haro Ana Cid, López Manuel Rodriguez, Massanet Antonio Palomero, Antonio Shally Marcellini, Guaita Saturnino Haya, Pellicer Javier García, Andrés Jose Luis Poveda, Boix Santiago Bonanad

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Extended half-life factor IX concentrates (FIX-EHL) have been shown to improve clinical outcomes and reduce treatment burden in patients with hemophilia B (HB).

OBJECTIVES

To analyze the differences in pharmacokinetic (PK) and clinical parameters one year before and after the PK-guided switch from standard half-life FIX (FIX-SHL) to FIX-EHL in patients with severe/moderate HB on prophylaxis.

METHODS

A multicenter, comparative, observational, sequential, retrospective, and multidisciplinary study was conducted. PK parameters were calculated with WAPPS-Hemo®, and annualized total (ABR) and joint bleeding rates, the t1/2 ratio and area under the curve (AUC), FIX consumption, infusion frequency, and cost were recorded.

RESULTS

A total of 21 patients (9 pediatric and 12 adult) with HB who switched from FIX-SHL to FIX-EHL were analyzed. All PK parameters improved significantly, with median improvement ratios for t1/2 and AUC of 4.1 (IQR: 3.4-4.8) and 4.2 (IQR: 2.6-5.0), respectively. Regarding clinical outcomes, the difference in ABR reached statistical significance and among the 6 patients with target joints, 5 (83.3 %) achieved resolution after switching. Infusion frequency and weekly dose were reduced by 50.0 % and 56.3 %, respectively, avoiding 52.1 (IQR: 26.1-67.8) injections and 130,357.3 (IQR: 5142.9-203,357.3) IU of FIX per patient per year. However, the switch resulted in an additional cost of € 28,254.9 (IQR: 4432.1- 44,060.8) per patient per year.

CONCLUSIONS

The PK-guided switch from FIX-SHL to FIX-EHL was associated with improvements in all PK parameters, and a significant clinical benefit was also demonstrated with the reduction of the bleeding rates. Following the switch, the weekly dose and administration frequency were reduced; however, this did not result in a cost reduction.

Для цитирования: Chovi-Trull Maria, Megías-Vericat Juan Eduardo, Palanques-Pastor Tomás, Haro Ana Cid, López Manuel Rodriguez, Massanet Antonio Palomero, Antonio Shally Marcellini, Guaita Saturnino Haya, Pellicer Javier García, Andrés Jose Luis Poveda, Boix Santiago Bonanad. Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric study.. Thrombosis research. 2026. DOI: 10.1016/j.thromres.2025.109580.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.